Product Description
ABBV-2222 (formerly GLPG2222) is a type of CFTR modulator called a corrector. (Sourced from: )
Mechanisms of Action: CFTR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galapagos
Company Location: 2800 MECHELEN C9 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| M23-492 FE | P1 |
Completed |
Cystic Fibrosis |
2022-12-21 |
28% |
| M23-492 FE | P1 |
Completed |
Cystic Fibrosis |
2022-12-21 |
28% |
| ABBV-576 DDI | P1 |
Completed |
Cystic Fibrosis |
2022-11-29 |
21% |
| ABBV-576 DDI | P1 |
Completed |
Cystic Fibrosis |
2022-11-29 |
21% |